Panel Discussion: Patient Navigation (Spring 2023 Cancer Policy Roundtable)
NCCS’s bi-annual Cancer Policy Roundtable (CPR) convenes stakeholders in the cancer community to discuss pressing issues related to cancer research, development of new cancer therapies, and the delivery of quality cancer care. Participants include cancer survivors, advocates, providers, payers, researchers, government officials, and industry representatives.
Note: All times Eastern. Session times subject to change.
Panel Discussion
This panel will explore emerging trends in cancer care delivery, examining the expanding ecosystem of providers beyond traditional oncology practices. The discussion will focus on how various entities — from care networks to supportive care organizations — are reshaping service delivery, care coordination, and patient experience, while addressing key questions about system transparency, quality improvement, and cost management.
Susan Hedlund, MSW, LCSW
Director, Supportive Care Initiative
The Sheri and Les Biller Family Foundation
Panel Discussion
This panel discussion will explore how artificial intelligence is transforming cancer diagnosis, treatment planning, and patient care, from accelerating drug discovery to improving the accuracy of medical imaging analysis. The session will examine both the exciting potential of AI to enhance clinical decision-making and patient outcomes, as well as critical challenges around data quality, algorithmic bias, clinical validation, and the evolving role of health care providers.
Panel Discussion
This panel will explore evolving approaches to managing health care costs and quality through utilization review processes and prior authorization requirements. The discussion will examine emerging technologies, policy changes, and operational strategies that payers and providers are implementing to streamline authorization workflows while ensuring appropriate care delivery.
Babs Wallace Drummond
Stage 4 Breast Cancer Survivor
Aspiring to chip away at the stigma and toxic positivity that often surrounds illness, Babs hopes to learn more about media advocacy to support powerful storytelling.
Babs believes that highlighting the full range of breast cancer experiences can encourage patient self-advocacy, inspire awareness and fundraising campaigns beyond October, and build more inclusive community spaces.
Babs feels her best in a dramatic sleeve or during a slow morning with her husband and their dog, Valentine. She connects with her siblings on the phone several times a day, is itching to get back into the ceramics studio, and genuinely enjoys working in spreadsheets.
Andrea Hans
Public Policy Manager, NCCS
Andrea Hans managed public policy at the National Coalition for Cancer Survivorship. Her breast cancer diagnosis in 2021, as an otherwise young healthy adult who found her own lump and was repeatedly told she was “too young”, served as a call to action. With a background in public health, Andrea has become an active voice in health policy and advocacy.
Justin Bekelman, MD
Co-Founder, Chief Executive Officer
Daymark Health
Dr. Bekelman is a physician with and former Chief of the Genitourinary Oncology Service in the Department of Radiation Oncology at Penn Medicine. Penn Medicine’s Department of Radiation Oncology, with locations in the greater Philadelphia region and New Jersey, is a world leader in patient care, cancer research, and education and offers today’s latest technology and treatment options. Over the years, Penn Medicine and Penn Radiation Oncology have received many prestigious awards, honors, and recognition for our commitment to providing our patients with the highest quality clinical care. Dr. Bekelman specializes in the early detection, surveillance and treatment of prostate cancer. We work with clinical experts from urology, medical oncology, radiology, pathology, and advanced practice nursing to improve cancer control, outcomes, and quality of life for our patients. Dr. Bekelman also has expertise in the treatment of testicular and bladder cancer.
Justin E. Bekelman, M.D., is the founding Director of the Penn Center for Cancer Care Innovation at the Abramson Cancer Center, the Marietta and Howard Stoeckel Professor of Radiation Oncology, Medicine, and Medical Ethics and Health Policy at the Perelman School of Medicine, Faculty in the Center for Health Incentives and Behavioral Economics, and Senior Fellow at the Leonard Davis Institute for Health Economics, all at the University of Pennsylvania. Dr. Bekelman leads research programs to improve the length and quality of life for patients with cancer. His research focuses on health care delivery, payment reform and cancer care transformation, integrating methods from the fields of innovation, epidemiology, clinical trials, health economics and public policy. Dr. Bekelman’s research has appeared in high-impact scientific journals and has been featured by media outlets in the United States, Canada, Europe, Asia, and Latin America. His work has been funded by the National Cancer Institute, the American Cancer Society, the Patient-Centered Outcomes Research Institute, the Commonwealth of Pennsylvania, and philanthropic sources. He has served as an advisor to the Centers for Medicare and Medicaid Services (CMS) on cancer care payment reform and innovation. Dr. Bekelman is an elected member of the American Society for Clinical Investigation and a member of the National Cancer Policy Forum of the National Academies of Science, Engineering, and Medicine.
Dr. Bekelman completed his undergraduate studies at Princeton University in the Princeton School of Public and International Affairs and his medical training at Yale University, Johns Hopkins, and Memorial Sloan Kettering Cancer Center. Previously, he was a management consultant at the Kalchas Group, advising senior executives of health care and insurance clients on corporate strategy. Dr. Bekelman also served as Special Assistant to the Under Secretary of Defense in the US Department of Defense. He is a board-certified radiation oncologist and practicing physician at the University of Pennsylvania Perelman School of Medicine.
Amy Hillsman, MSN, ANP-BC
Senior Director, Virtual Care Center
Reimagine Care
Amy Hillsman is the Senior Director of the Virtual Care Center at Reimagine Care. She is a nurse practitioner with oncology specialty certification from the University of Maryland, Baltimore. She has over twenty years of oncology experience working across academic, community and research medical centers.
About Reimagine Care: We believe people living with cancer deserve a better patient experience; to feel their best and to spend as much time as possible with the people they love, doing the things that bring them joy. Reimagine Care integrates clinical oncology experts and robust, enabling technologies to deliver a high-touch, individualized cancer treatment and recovery experience from home. This holistic approach relies on the combination of empathy and knowledge of our clinical care team with our thoughtfully designed and easy-to-use platform.
Our vision and our approach fuel the delivery of high-quality, safe, home-centered, coordinated cancer care that makes care more patient-centric, accessible, affordable, and the first choice for patients everywhere.
Extending Care Beyond the Clinic.
Rebecca Miksad, MD, MPH
Chief Medical Officer
Color Health
Dr. Rebecca Miksad is a mission-driven Physician-Scientist with extensive expertise in cancer and patient-centric health technology and AI solutions. As Chief Medical Officer at Color Health, she oversees Color’s medical and clinical functions, driving the expansion of cancer screening, diagnostics, care navigation, and survivorship tools for program participants. Dr. Miksad previously founded and led the Strategic Affairs team and Research Unit at Flatiron Health, developing pioneering healthtech products and establishing industry standards for real-world data. Her work has influenced FDA guidances and advanced Health Equity initiatives. With over 100 scientific publications, Dr. Miksad is an internationally recognized leader in oncology, clinical trials and data science. She established the first High Risk Cancer Genetics clinic at Boston Medical Center, where she is an Associate Professor and continues to care for patients. She previously directed the Gastrointestinal Cancer program at Beth Israel Deaconess Medical Center and conducted NIH-funded research. Clinically trained as a medical oncologist, Dr. Miksad holds an MD with Honors from Cornell University and an MPH in Clinical Effectiveness from Harvard University.
Hil Moss, MBA, MPH
Co-Founder and CEO
OncoveryCare
A young breast cancer survivor, Hil is an active patient advocate, mentor, and writer in the cancer community, and dedicates her time to raising awareness around the importance of early detection and longitudinal survivorship care. Prior to founding OncoveryCare, Hil worked with a range of healthcare companies including Hologic, LUCA Biologics, Thrive Earlier Detection, OncoHealth, and Amwell. She holds a BA from Princeton University and an MBA/MPH from Yale University, where she was the Co-Chair of the 2022 Yale Healthcare Conference and a Solomon Center Fellow at Yale Law School. Prior to transitioning into the healthcare space, Hil was the Associate Director of Strategy and Innovation at New York-based consultancy LaPlaca Cohen, where she advised the nation’s leading arts and culture organizations on planning for the future. She lives in Somerville, MA, where she enjoys getting outside, spending time with family and friends, and playing with her dog, Levi.
Samyukta (Sam) Mullangi, MD, MBA
Senior Medical Director of Oncology
Thyme Care
Sam is a senior medical director at Thyme Care, a population health company in cancer aiming to further the transition from fee-for-service to value-based care, and improve patient journeys in the process. She is also a practicing medical oncologist at Tennessee Oncology, and holds a special interest in health policy, specialty pharmacy, and care delivery innovation.
She trained at the University of Michigan and Memorial Sloan Kettering, and received an MD-MBA from Harvard. Her writing has appeared in The New England Journal of Medicine, JAMA, Health Affairs, Harvard Business Review, and Scientific American.
Yousuf Zafar, MD, MHS
Chief Medical Officer
AccessHope
Dr. Zafar leads AccessHope’s clinical infrastructure. He is a practicing oncologist, an adjunct professor at Duke University, and a Fellow of the American Society of Clinical Oncology who has authored more than 100 publications. Most recently he was senior vice president of Medical Informatics at Optum and Change Healthcare, prior to its acquisition by Optum. In this role, he oversaw development and implementation of innovative solutions that leverage real-world evidence, precision medicine, digital health and data analytics to improve patient outcomes, optimize care delivery and reduce healthcare costs. Prior to Change Healthcare, Dr. Zafar was at the Duke Cancer Institute, where he served first as director of Healthcare Innovation, and then as chief quality and innovation officer. He earned an M.D. at The University of Toledo College of Medicine and Life Sciences. He completed his oncology training and earned an M.H.S. in Health Sciences in Clinical Research from Duke University.
Shelley Fuld Nasso, MPP
Chief Executive Officer
NCCS
As Chief Executive Officer, Shelley Fuld Nasso leads the public policy activities of NCCS at a time of rapid and fundamental health care system change. Shelley joined NCCS in December 2012 and was named CEO in October 2013.
Prior to joining NCCS, Shelley served in leadership roles at Susan G. Komen, where she leveraged Komen’s grassroots network in Washington, D.C., and in state capitals. There she built relationships with policymakers and partner organizations and led a team of staff and volunteer leaders to influence state budgets and legislation. Under her leadership, Komen successfully secured $80 million in state funding for cancer screening and treatment for uninsured and under-insured women. She and her team also expanded the Komen grassroots advocacy program from a pilot of seven affiliates to more than 100 affiliates across the country engaged in federal and state advocacy efforts. Shelley has also served as Director of Community Philanthropy at The Dallas Foundation and held management positions at communications and technology enterprises. She is a graduate of Rice University and holds a Master of Public Policy from the Harvard Kennedy School.
Shelley’s commitment to the work of NCCS is strongly tied to the experiences in the cancer care system of her dear friend, Dr. Brent Whitworth, a beloved physician who was diagnosed with stage IV cancer days before his 42nd birthday and who passed away 19 months later. Through Brent’s experiences, Shelley witnessed the strengths and flaws of the cancer care system and embraces the notion that policy change can make cancer care better for patients and caregivers. Shelley and her husband Michael live in Maryland and are the parents of three young boys.
Susan Hedlund, MSW, LCSW
Director, Supportive Care Initiative
The Sheri and Les Biller Family Foundation
Susan Hedlund, LCSW, has been a social worker in the health care field for more than thirty years and has extensive experience working with individuals and families facing life threatening illness and loss. Until joining the Biller Family Foundation, she was the Director of Patient and Family Services at the Knight Cancer Institute at OHSU. She was an associate professor at the School of Medicine at Oregon Health & Sciences University, and the Graduate School of Social Work at Portland State University, as well as teaching in the palliative care certificate program at the University of Washington.
She is a past president of the National Association of Oncology Social Work, and received their Leadership Award in 1999, and the national American Cancer Society Quality of Life Award in 2009.
She was a 2013 recipient of Sojourn’s Award from the Cambia Foundation acknowledging innovations in palliative care.
She publishes on topics related to coping with illness, end of life issues, and loss, most recently in the Oxford University’s Textbook on Social Work in Palliative Care and the Handbook of Oncology Social Work., and is the lead editor for the Oxford University Press Oncology and Palliative Social Work: Psychosocial Care for People Coping with Cancer. She works with professional caregivers on issues of promoting resilience and attending to grief, burnout, and compassion fatigue.
She is the mental health provider on Oregon’s Disaster Medical Assistance team.
Jennifer Bires, MSW, LCSW, OSW-C
Executive Director, Life with Cancer and Patient Experience
Inova Schar Cancer Institute
Jennifer Bires is an innovative leader in psychosocial oncology, dedicating over 15 years to developing compassionate, patient-centered supportive care programs for cancer patients and their families.
As the Executive Director of Integrative and Psychosocial Oncology at Inova Schar Cancer Institute, Jennifer leads a multidisciplinary team of oncology behavioral health therapists, social workers, nurse navigators, and oncology dieticians. Her comprehensive approach ensures patients and their support networks receive holistic psychosocial care and education at no cost, helping them navigate the complex emotional landscape of cancer.
Jennifer oversees Inova’s Arts and Healing program, pioneering the use of artistic expression as a powerful healing modality. Her clinical expertise spans critical areas including technology’s intersection with mental health, sexual health, young adult cancer experiences, and end-of-life care.
Currently pursuing her PhD in Palliative Care at the University of Maryland, Baltimore, Jennifer is conducting groundbreaking research exploring psychedelics as a potential behavioral health treatment for cancer patients. Her academic journey reflects her commitment to innovative, compassionate care approaches.
Jennifer holds a Master of Social Work from Washington University in Saint Louis and a Bachelor’s degree from Clemson University. Her leadership extends beyond clinical work through significant board positions, including roles with the Association of Oncology Nurse Navigators, the Association of Cancer Care Centers, and the American Cancer Society National Navigation Round Table. She is a past chair of the Board of Oncology Social Work.
Irene Dankwa Mullan, MD, MPH
Chief Health Officer, Chief Medical Officer, Marti Health
Adjunct Professor, George Washington University-Milken Institute School of Public Health
Dr. Irene Dankwa-Mullan is an industry physician, consultant, scientist, thought leader, health equity scholar with over 20 years of diverse regional and national leadership experience in primary care, healthcare systems, research, and the community. She is Chief Health Equity Officer and Deputy Chief Health Officer at Merative, formerly IBM Watson Health. IBM created the IBM Watson Health unit, bringing together technologies, data and analytics, that would ultimately make up Merative. She was a member of the IBM Industry Academy, a selected community of pre-eminent leaders to drive innovation and engage in cutting-edge work for the industry. She previously served as Deputy Director for extramural scientific programs at NIMHD, NIH. While at the NIH, she was active on several key strategic committees, including many that were cross-sectoral promoting health equity and health in all policies. She is the lead editor of the resource textbook ‘The Science of Health Disparities Research’ published by Wiley, designed to guide the research community identify relevant questions, design approaches, and conduct studies to advance the discipline. This was a collaborative effort with NIMHD scientists and thought leaders including community advocates. She serves on various advisory boards and mentors in STEM. Dankwa-Mullan has published widely on health equity, applied artificial intelligence (AI) and machine-learning, including ethical and responsible AI for social good.
Andrew Hantel, MD
Department of Medical Oncology, Dana-Farber Cancer Institute
Faculty Member, Harvard Medical School Center for Bioethics
Andrew Hantel, MD is an Assistant Professor of Medicine at Harvard Medical School and faculty member in the Divisions of Leukemia and Population Sciences at Dana-Farber Cancer Institute and the HMS Center for Bioethics. He received his MD from Loyola University Chicago; trained in internal medicine, adult hematology/oncology, and medical ethics at the University of Chicago; and completed a post-doctoral fellowship in cancer population sciences at the Dana-Farber/Harvard Cancer Center. Dr. Hantel’s lab leverages health services and care delivery methods to address ethical dilemmas in cancer discovery and delivery. His current work focuses on equity in the contexts of research participation, artificial intelligence, and climate change.
Maya Said, ScD
Founder and Chief Executive Officer
Outcomes4Me
Dr. Said is the Founder and CEO of Outcomes4Me, a health technology company focused on empowering cancer patients with personalized, evidence-based navigation and improving outcomes through better access to innovation. Prior to founding Outcomes4Me, she was Senior Vice President of Global Market Access & Policy at Novartis Pharmaceuticals and Vice President of Strategy & External Innovation at Sanofi.
Dr. Said is a strong advocate for life sciences innovation and serves on the Board of Directors of Transgene, Pieris Pharmaceuticals, and Home Biosciences. She was a founding member of the Boston Consulting Group Strategy Institute.
Troy Tazbaz
Former Director of Digital Health
U.S. Food and Drug Administration
Troy currently serves as Senior Vice President of Data Center Planning in Corporate Development. He was previously the Director of the Digital Health Center of Excellence at the FDA. Mr. Tazbaz combines a long career in IT with long and personal involvement in healthcare.
Most media outlets focus on Mr. Tazbaz’s recent career in cloud infrastructure at Oracle and earlier work in social software at Ning. However, some of his most important work is his voluntary and very personal engagement in patient care, especially in Hematology and Oncology.
Since 2010 Troy Tazbaz has been involved in campaigning for The Leukemia & Lymphoma Society, a Patient Advocacy Group, and the largest nonprofit dedicated to fighting blood cancer.
Mr. Tazbaz has deeply personal experience in oncology treatment and care. He was supporting his wife, Brynn Fowler in her patient journey as documented on her blog, The Millennial with Cancer. Mrs. Fowler was diagnosed with Stage IV Colon Cancer at the age 37. Now, after Mrs. Fowler has passed away, the website is still maintained by Mr. Tazbaz as The Continuum Diaries.
Dave Adler
Vice President, Advocacy
American Society for Radiation Oncology (ASTRO)
Dave Adler is the Vice President of Advocacy for the American Society for Radiation Oncology (ASTRO), the leading radiation oncology professional society in the world. In this role, Dave leads the development and execution of ASTRO’s legislative and regulatory agenda, including advocacy with Congress, federal agencies and private payers on issues involving Medicare payment, cancer research, insurance coverage and coding. During his 18 years with ASTRO, Dave has served in several roles managing and directing the Society’s legislative and health policy initiatives. Prior to joining ASTRO, Dave served as Director of Government Affairs at the American Health Quality Association (AHQA), where he lobbied Congress and federal agencies on behalf of Medicare’s Quality Improvement Organizations. Before joining AHQA, Dave was a reporter for CD Publications, covering health care and welfare funding news in Congress and the administration. Dave also previously served as a business reporter for the Capital-Gazette newspaper company, covering Anne Arundel County, Maryland. Dave has a Master’s degree in Journalism from Northeastern University in Boston, and he graduated with a Bachelor’s degree in International Affairs from The George Washington University in Washington, DC.
Kim Czubaruk, JD
Associate Vice President of Policy
CancerCare
Kim Czubaruk is the Associate Vice President of Policy at CancerCare. For over 80 years, CancerCare has empowered millions of people affected by cancer through free counseling, resource navigation, support groups, educational resources, advocacy, and direct financial assistance. CancerCare’s oncology social workers improve the lives of people diagnosed with cancer, caregivers, survivors and the bereaved, by addressing their emotional, practical and financial challenges. Kim is a health policy expert who uses her prior experience in civil litigation and disability law to help improve patient care, coverage, and outcomes. As CancerCare’s Associate Vice President of Policy, Kim oversees the direction of CancerCare’s advocacy efforts by developing and implementing strategic projects and initiatives, cultivating alliances, and advancing the organization’s national policy agenda. Kim earned her Juris Doctor, with honors, from George Washington University Law School and her Bachelor of Arts degree, magna cum laude, in political science from Union College. Kim brings twenty-five plus years of non-profit experience and a commitment to driving meaningful patient-centered health policy solutions.
Karen Hagerty, MD
Chief Regulatory Affairs Officer
Association for Clinical Oncology
Karen Hagerty, MD received a BA from The American University in 1992, followed by a degree in medicine from the George Washington University School of Medicine and Health Sciences in 1998. Following an internship at Georgetown University, she helped lead projects for a government contractor at the National Cancer Institute, the National Human Genome Research Institute, the Office of Rare Diseases, and others. Dr. Hagerty originally joined the American Society of Clinical Oncology (ASCO) in 2005, where she assisted in development of ASCO’s clinical practice guidelines and led staff focused on physician reimbursement and practice issues. She currently leads ASCO’s regulatory team and focuses on a range of issues impacting access to high quality cancer care.
Tricia Neuman, ScD
Senior Vice President, Executive Director for Program on Medicare Policy
KFF
Tricia Neuman is senior vice president of KFF and executive director of its Program on Medicare Policy. She oversees KFF’s policy analysis and research pertaining to Medicare, and health coverage and care for aging Americans and people with disabilities. A widely cited Medicare policy expert, Dr. Neuman focuses on topics such as the health and economic security of older adults; the role of Medicare Advantage plans, Medicare and out-of-pocket spending trends; prescription drug costs, payment and delivery system reforms; and policy options to strengthen Medicare for the future. She has written numerous papers pertaining to Medicare, has been invited several times to present expert testimony before Congressional committees, and has appeared and been quoted as an independent expert by major national media outlets. Dr. Neuman was nominated by President Biden in 2022 to serve as a member of the Board of Trustees of the Medicare, Social Security, and Disability Insurance Trust Funds.
Before joining KFF in 1995, Dr. Neuman served on the professional staff of the Ways and Means Subcommittee on Health in the U.S. House of Representatives and on the staff of the U.S. Senate Special Committee on Aging, working on health and long-term care issues.
Dr. Neuman received a bachelor’s degree from Wesleyan University, a master’s in health finance and management from the Johns Hopkins School of Public Health, and a doctorate in health policy and management, also from the Johns Hopkins School of Public Health.
Amar Rewari, MD, MBA, FASTRO
Chief of Radiation Oncology, Luminis Health
Adjunct Assistant Professor, Johns Hopkins University School of Medicine
Vice-Chair, Health Policy Council, ASTRO
Dr. Amar Rewari is a national leader in radiation oncology health policy and payment reform serving as the Vice-Chair of the Health Policy Council on the American Society for Radiation Oncology (ASTRO) Board of Directors and a co-host of the Value Health Voices podcast. He was a member of the inaugural class of the ASTRO Health Policy Fellowship. After completing his fellowship, Dr. Rewari immersed himself in the work of the American Medical Association (AMA) Resource Based Value Scale Update Committee (RUC) which led to his appointment as ASTRO’s RUC Advisor. Dr. Rewari also serves as Chair of the ASTRO Code Development and Valuation Committee (CDVC), ASTRO Corporate Relations Committee Vice-Chair, and ASTRO Corporate Advisory Council Vice-Chair. Prior to his appointment to the ASTRO Board, Dr. Rewari served as the ASTRO Health Policy Committee Chair and Radiation Oncology Economics Committee Chair for the American College of Radiology (ACR).
Dr. Rewari completed a John Hopkins Certificate Course in proton therapy and currently treats all disease sites at Anne Arundel Medical Center utilizing the latest radiation techniques while practicing compassionate, personalized, evidence-based medicine. He is a Principal Investigator on several clinical research trials, has authored numerous publications and is a frequently invited speaker at international medical conferences. He has previously worked in the Office of the Chairman at Aetna as a Health Policy Associate, in the HealthCare group at Credit Suisse as an investment banker, and currently serves as Chairman of the Board for Fund for Education Abroad, the largest study abroad scholarship provider for students of color and economic disadvantage. Dr. Rewari is passionate about supporting scholarships that empower students to explore the world and help them gain the global perspective that will guide them throughout their lives. In his spare time, Dr. Rewari is an avid traveler and foodie who enjoys scuba, sailing, skiing, and tennis.
Dr. Rewari graduated summa cum laude and Phi Beta Kappa with a degree in political science from Temple University. He received his MD and MBA degrees from Yale University School of Medicine and Yale University School of Management and stayed at Yale-New Haven Hospital to complete an Internal Medicine internship. He attended Rutgers University for his radiation oncology residency, during which time he was named Chief Resident, received the Dean’s Research Award, and ASTRO’s highest award for clinical research at their annual meeting.
Otis Brawley, MD
Bloomberg Distinguished Professor of Oncology and Epidemiology
Johns Hopkins University School of Medicine
NCCS Board Member
Otis W. Brawley, MD is a globally recognized expert in cancer prevention and control. He has worked to reduce over-screening of medical conditions, which has revolutionized patient treatment by increasing quality of life and reducing health disparities.
Dr. Brawley’s research focuses on developing cancer screening strategies and ensuring their effectiveness. He has championed efforts to decrease smoking and implement other lifestyle risk reduction programs, as well as to provide critical support to cancer patients and concentrate cancer control efforts in areas where they could be most effective. Dr. Brawley currently leads a broad interdisciplinary research effort on cancer health disparities at the Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center, striving to close racial, economic, and social disparities in the prevention, detection, and treatment of cancer in the United States and worldwide. He also directs community outreach programs for underserved populations throughout Maryland.
Dr. Brawley joined Johns Hopkins University as a Bloomberg Distinguished Professor in 2019 from the American Cancer Society and Emory University. Dr. Brawley is a board member of the National Coalition for Cancer Survivorship.
Elizabeth Williams, MS
Senior Policy Manager, Program on Medicaid & Uninsured
KFF
Elizabeth (Liz) Williams is a senior policy manager with KFF’s Program on Medicaid and the Uninsured, where she focuses on analysis of state fiscal conditions, Medicaid prescription drug spending and utilization, and children’s health coverage and access. Prior to joining KFF, Liz worked in program evaluation at DC’s Children’s Law Center and conducted data analysis for the City of Philadelphia and the University of Pennsylvania’s Counseling and Psychological Services. She holds a Bachelor’s in Mathematics and Statistics from James Madison University, and a Master’s in Social Policy with a certificate in Data Analytics for Social Policy from the University of Pennsylvania.
Registration has closed for this event.
If you were invited to attend, please send any questions to Nadine Dorvelus at ndorvelus@canceradvocacy.org.
(as of 3/14/2025)
National Coalition for Cancer Survivorship
8455 Colesville Road | Suite 930 | Silver Spring, MD 20910
info@canceradvocacy.org | (877) NCCS-YES
Privacy Policy | Terms and Conditions
Copyright © 1995-2024 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.
Founder
Northeast Regional Cancer Institute
“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”
—Karen M. Saunders
President, Northeast Regional Cancer Institute
Social Media Toolkit
We encourage speakers and participating organizations to engage with NCCS on social media throughout the Spring 2025 Cancer Policy Roundtable. Please contact NCCS Communications and Marketing Manager Kara Kenan at kkenan@canceradvocacy.org with any questions or concerns.
Hashtags
Sample Social Posts
We have provided some sample posts below for each social platform.
Sample Posts for Attendees
X
Attending @CancerAdvocacy’s #CPR25 today to engage with leaders in cancer care, tech, & policy. From AI to Medicaid—every topic impacts survivors. Grateful to be part of this space. #canceradvocacy #cancersurvivorship
I’m proud to represent [organization] at @CancerAdvocacy’s Spring 2025 Cancer Policy Roundtable. Great insights into the future of cancer care. #CPR25
Thank you, @CancerAdvocacy, for hosting the Spring 2025 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR25
LinkedIn
I’m attending @NCCSCancerAdvocacy’s Spring 2025 Cancer Policy Roundtable today with policy experts, researchers, clinicians, and advocates. Discussions include Medicaid, AI, supportive care, and more—centered on improving outcomes for cancer survivors. #CPR25 #canceradvocacy
I’m proud to represent [organization] at the @NCCSCancerAdvocacy’s Spring 2025 Cancer Policy Roundtable. Great insights into the future of cancer care. #CPR25
Thank you, @NCCSCancerAdvocacy’s, for hosting the Spring 2025 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR25
Instagram
At @cancersurvivorship’s #CPR25 today! Grateful for the chance to learn from experts in #cancerpolicy, #AIinhealthcare, and supportive care—always focused on survivors. #cancersurvivorship #canceradvocacy
I’m proud to represent [organization] at @cancersurvivorship’s Spring 2025 Cancer Policy Roundtable. Great insights into the future of cancer care. #CPR25
Thank you, @cancersurvivorship, for hosting the Spring 2025 Cancer Policy Roundtable. I’m excited for the future. #CPR25
Facebook
I’m attending the Spring 2025 Cancer Policy Roundtable, hosted by @cancersurvivorship. Today’s panels explore the future of cancer care—from Medicaid and AI to supportive care. Proud to be part of this important conversation. #CPR25 #canceradvocacy #cancersurvivorship
I’m proud to represent [organization] at @cancersurvivorship’s Spring 2025 Cancer Policy Roundtable. Great insights into the future of cancer care. #CPR25
Thank you, @cancersurvivorship, for hosting the Spring 2025 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR25
Sample Posts for Speakers
X
Honored to participate in @CancerAdvocacy’s #CPR25, discussing AI, Medicaid, supportive care & more. Grateful to help advance policies that center survivors in cancer care. #cancersurvivorship #canceradvocacy
Thank you, @CancerAdvocacy, for inviting me to speak at today’s Spring 2025 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR25
LinkedIn
Proud to speak at @NCCSCancerAdvocacy’s Spring 2025 Cancer Policy Roundtable. Today’s conversations spanned AI, Medicaid, supportive care, and more—highlighting the urgent need to center survivors in cancer care policy. #CPR25 #cancersurvivorship #cancerpolicy
Thank you, @NCCSCancerAdvocacy, for inviting me to speak at today’s Spring 2025 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR25
Instagram
Proud to speak at @cancersurvivorship’s #CPR25 Cancer Policy Roundtable! Today’s sessions explored the future of #cancerpolicy, from AI and Medicaid to supportive care and access. Honored to be part of this work. #cancersurvivorship #canceradvocacy
Thank you, @cancersurvivorship, for inviting me to speak at today’s Spring 2025 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR25
Facebook
Thank you to @cancersurvivorship for the opportunity to speak at the Spring 2025 Cancer Policy Roundtable. It was an honor to join leaders in cancer care, advocacy, and policy to discuss the future of survivorship-centered care. #CPR25 #cancersurvivorship #canceradvocacy
Thank you, @cancersurvivorship, for inviting me to speak at today’s Spring 2025 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR25